Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-05-06
1998-08-25
Wilson, James O.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 46, 514 47, 514 48, 514 49, 514 50, 514 51, 536 2714, 536 2721, 536 276, 536 277, 536 278, 536 2781, 536 282, 536 285, 536 2851, 536 2852, 536 2853, 536 2854, 536 2855, 544242, 544243, 544244, 544264, A61K 3170
Patent
active
057983402
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to novel nucleotide analog amidates and esters, their pharmaceutically acceptable acid addition salts, a process for their production, and to their use. The nucleotides of the present invention exhibit antitumor/antineoplastic activity, a broad spectrum of antimicrobial activity and certain other desirable activities.
Compounds related to the nucleotide analogs of the present invention may be found in: U.S. Pat. No. 5,043,339, 5,108,994 and 5,166,198; EP 206 459; EP 253 412; EP 269 947; EP 270 885; EP 319 228; EP 343 133; EP 398 231; EP 404 296; EP 465 297; EP 468 119; EP 468 866; EP 479 640; EP 481 214; EP 494 370; EP 531 597; PCT/GB91/01171; PCT/US92/01020; PCT/US92/05208; WO 91/19721; Bronson et al, Bioorg Medicinal Chem Lett (1992) 2:685-690; Bronson et al, J Med Chem, (1989) 32:1457-1463; Bronson et al, Nucleotide Analogs as Antiviral Agents, ACS Symposium Series 401, J. C. Martin, Ed., p. 72-87, American Chemical Society, Washington, D.C. (1989); Colla, et al, J Med Chem (1983) 26:602-604; Curley, et al, Antiviral Res (1990) 14:345-356; De Clercq, et al, Nature, (1986) 323:464-467; Farrow, et al, J Med Chem (1990) 33:1400-1406; Farquhar, et al, J. Pharm Sci (1983) 72:324-325; Freed, et al, Biochem Pharmacol (1989) 19:3193-3198; Freeman, et al, J Med Chem (1992) 35:3192-3196; Gabrielsen, B., et al, Antiviral Res Suppl I (1992) 17:149; Gumport, et al, Proc Natl Acad Sci (1971) 2559-2563; Juodka, et al, Coll Czech Chem Commun (1974) 39:963-968; Kim, et al, Bioorg Medicinal Chem Lett (1992) 2:367-370; Kim, et al, Tet Lett (1992) 33:25-28; Kim, et al, J Med Chem (1990) 33:1207-1213; Kumar, et al, J Med Chem (1990) 33:2368-2375; McGuigan, et al, Antiviral Chem Chemother (1993) 4:97-101; McGuigan, et al, Antiviral Res (1991) 15:255-263; Rosenberg, et al, Coll Czech Chem Commun (1988) 53:2753-2777; Rosenberg, et al, Coll Czech Chem Commun (1988) 52:2792-2800; Rosenberg, et al, Coll Czech Chem Commun (1988) 52:2801-2808; Starrett, et al, Antiviral Res (1992) 19:267-273; Yu, et al, J Med Chem (1992) 35:2958-2969; Wolff-Kugel, et al, Tet Lett (1991) 32:6341-6344.
WO 92/13869 discloses certain esters of methylene phosphonate nucleotide analogs.
A characteristic of nucleotide analogs or nucleotides having a phosphonate or a phosphate group is the presence of one or two negative charges associated with the phosphorus group at physiologic pH. The charge associated with moieties such as phosphate or phosphonate groups is believed to generally limit bioavailability by limiting cell membrane permeation via passive diffusion (Liebman, et al, J. Biol. Chem., (1955) 216:823-830; Roll, et al, J Biol Chem, (1956) 220:439-444; Srivastava, et al, Bioorg Chem (1984) 12:118-129; Palu, et al, Antiviral Res (1991) 16:115-119; Sastry, et al, Mol Pharmacol (1992) 41:441-445). These compounds are often, therefore, given parenterally in order to enhance bioavailability by increasing serum or intracellular levels.
Other characteristics of nucleotide analogs that can limit their efficacy include unfavorable pharmacokinetic or pharmacodynamic properties, insufficient potency and/or unfavorable toxicity characteristics.
Studies were conducted to ameliorate one or more of the above-mentioned problems associated with nucleotide analog drugs. The present invention includes novel nucleotide analogs that are hydrolyzable in vivo. The nucleotide analogs can have improved bioavailability, improved pharmacokinetic or pharmacodynamic properties, enhanced potency and/or improved toxicity characteristics compared to the corresponding unmodified nucleotide analog. Methods to synthesize and use the compounds and methods to obtain and use antibodies that recognize the compounds are also disclosed.
SUMMARY OF THE INVENTION
In a principal embodiment, the objects of this invention are accomplished by a nucleotide analog amidate comprising a phosphonate radical wherein the improvement comprises an amino acid residue or polypeptide radical in which an amino group of the amino acid or polypeptid
REFERENCES:
patent: 3524846 (1970-08-01), Moffatt et al.
patent: 4590269 (1986-05-01), Prisbe et al.
patent: 4670424 (1987-06-01), MacCoss et al.
patent: 4724233 (1988-02-01), De Clercq et al.
patent: 4808716 (1989-02-01), Holy et al.
patent: 4968788 (1990-11-01), Farquhar
patent: 5043339 (1991-08-01), Beauchamp
patent: 5047533 (1991-09-01), Reist et al.
patent: 5142051 (1992-08-01), Holy et al.
patent: 5208221 (1993-05-01), Kim et al.
patent: 5247085 (1993-09-01), Harnden et al.
patent: 5302585 (1994-04-01), Yu et al.
patent: 5352786 (1994-10-01), Jindrich et al.
patent: 5527803 (1996-06-01), Halazy et al.
patent: 5591851 (1997-01-01), Alexander
patent: 5618793 (1997-04-01), Cooper
patent: 5618803 (1997-04-01), Bodor
patent: 5618964 (1997-04-01), Cheng
patent: 5656745 (1997-08-01), Bischofberger et al.
Alexander et al., Collect Czech Chem Commun, 59:1853 (1994).
Andrei et al, "Comparative Activity of Selected Antiviral Compounds against Clinical Isolates of Human Cytomegalovirus," Eur J Clin Microbiol Infect Dis 10(12):1026-1033 (1991).
Barnard et al, "Selective inhibition of cytomegalovirus by 9-(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxy-methyl)guanine," Antiviral Res 22:77-89 (1993).
Beres, "Synthesis and Antitumor and Antiviral Properties of 5-Halo-and 5-(Trifluoromethyl)-2'-deoxyuridine 3', 5'-Cyclic Monophosphates and Neutral Triesters," J Med Chem 29:1243-1249 (1986).
Bronson et al, "Synthesis and Biological Activity of Carbocyclic Guanine (PMEG)," Bioorg Med Chem Lett 2:685-690 (1992).
Bruice et al., "Hydrolysis of a Phosphate Diester by Simultaneous Carboxylate and Carboxyl Group Participation in a Rigid System with Kinetically Unfavorable Rotamers Frozen Out," J Am Chem Soc 117:3639-3640 (1995).
Charvet et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Phosphonoformate--and Phosphonoacetate--2',3'-Dideoxy-3'-thiacytidine Conjugates," J Med Chem 37:2216-2223 (1994).
Colla et al, "Synthesis and Antiviral Activity of Water-Soluble Esters of (1983).
Davies et al, "2'-Nor'2'-deoxyguanosine is an effective therapeutic agent for treatment of experimental herpes keratitis," Antiviral Res 7:119-125 (1987).
Duke et al., "In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine against cytomegaloviruses," Antiviral Res 6:299-308 (1986).
Engel, R., "Phosphonates as Analogues of Natural Phosphates," Chem Rev 77(3):349-367 (1977).
Farquhar et al, "Biologically Reversible Phosphate-Protective Groups," J. Pharm Sci 72:324-325 (1983).
Farrow et al, "Synthesis and Biological Properties of Novel Phosphotriesters: A New Approach to the Introduction of Biologically Active Nucleotides into Cells," J Med Chem 33:1400-1406 (1990).
Feng et al, "Combined treatment with 2'-nor-cGMP and ganciclovir against cytomegalovirus infection in a guinea pig model," Antiviral Res 19:193-206 (1992).
Field et al, "Efficacy of 2'-nor-cyclicGMP in treatment of experimental herpes virus infections," Antiviral Res 6:329-341 (1986).
Freed et al, "Evidence for Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem Pharm 38:3193-3198 (1989).
Freeman et al, "3'-Azido-3',5'-dideoxythymidine-5'-methylphosphonic Acid Diphosphate: Synthesis and HIV-1 Reverse Transcriptase Inhibition," J Med Chem 35:3192-3196 (1992).
Glazier et al., "Potent Topical Anti-Herpes Activity of a Lipophilic Phosphorous Prodrug for the Antiviral Agent PMEA," 8th International Conference on Antiviral Research, Santa Fe, NM p. A306-Poster (Apr. 23-28, 1995).
Harnden et al, "Synthesis and Antiviral Activity of 9-Alkoxypurines. 1. Med Chem 33:187-196 (1990).
Ho et al, "Intracellular Metabolism of the Antiherpes Agent 41:197-202 (1992).
Holy et al, "Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro," Antiviral Res 13:295-312 (1990).
Holy et al, "Synthesis of (3-Hydroxy-2-Phosphonyl
Arimilli Murty N.
Bischofberger Norbert W.
Jones Robert J.
Lee William A.
Louie Michael S.
Gilead Sciences, Inc.
Muenchau Daryl D.
Wilson James O.
LandOfFree
Nucleotide analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleotide analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleotide analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-36398